Plain Language Summaries is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • How to
  • FAQs
  • Publications
  • Advisory Panel
    • Plain Language Advisors
    • Scientific Content Advisors
  • Supporters
  • Blog
  • About us
  • Contact Us

aromatase inhibitor

22nd Apr 2025

Plain language summary: Palbociclib plus an aromatase inhibitor for HR+/HER2– metastatic breast cancer with lung or liver spread

This summary describes an article published in the medical journal Frontiers in Oncology in September 2023. The article reports results from a study that looked at breast cancer treatments for older patients aged 75 years or older. The study focused on a type of cancer called HR+/HER2- metastatic breast cancer. HR+/HER2- stands for hormone receptor-positive/human epidermal growth factor receptor 2-negative. This study evaluated whether older patients with this type of cancer benefited from the combination of two medicines – palbociclib and an aromatase inhibitor – compared with taking an aromatase inhibitor alone.
30th Apr 2024

Palbociclib plus an aromatase inhibitor for older patients with metastatic breast cancer

12th Apr 2023

Plain Language Summary: a real-world database analysis on prolonging the life of people with metastatic breast cancer in routine clinical practice by adding palbociclib to an aromatase inhibitor

Copyright © 2026 · Plain Language Summaries · Terms and conditions · Privacy policy · Cookie policy